A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors-Reference-Cited by-同舟云学术

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

Published:2021-03-08 Issue:4 Volume:39 Page:1089-1098
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Azaro Analia,Massard Christophe,Tap William D.,Cassier Philippe A.,Merchan Jaime,Italiano Antoine,Anderson Bailey,Yuen Eunice,Yu Danni,Oakley Gerard,Benhadji Karim A.,Pant Shubham^ORCID

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-021-01094-6.pdf

Reference24 articles.

1. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science. 284:770–776. https://doi.org/10.1126/science.284.5415.770

2. Allenspach EJ, Maillard I, Aster JC, Pear WS (2002) Notch signaling in cancer. Cancer Biol Ther 1:466–476. https://doi.org/10.4161/cbt.1.5.159

3. Takebe N, Miele L, Harris PJ et al (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 12:445–464. https://doi.org/10.1016/j.pharmthera.2013.09.005